Table 3.
PIPAC for pancreatic cancer
| Author, Year | Study design | Country | N | Age (Median) |
Tumor status | Technique | Time (min) |
Chemotherapy agent, dosage | MOS (months) |
Note |
|---|---|---|---|---|---|---|---|---|---|---|
|
Graversen, 2023 [8] |
Phase II trial | Denmark | 21 | 63 | Unresectable with PM | Close | 30–35 |
CIS-Dox (7.5 mg/m2- 1.5 mg/m2) |
8.2 | MOS since PM diagnosis = 15.6 months |
|
Nielsen, 2021 [63] |
Case series | Denmark | 16 |
Mean 59 |
Unresectable | Close | 30 |
CIS-Dox (7.5 mg/m2- 1.5 mg/m2) |
9.9 | - |
|
Di Giorgio, 2020 [60] |
Case series | Italy and France | 14 | 64 | Unresectable with PM | Close | 30 |
CIS-Dox (7.5 mg/m2- 1.5 mg/m2) Or Oxa (92 mg/m2) |
9.7 |
MOS since PM diagnosis = 16.2 months Pathological regression rate = 50% |
|
Graversen, 2017 [67] |
Case series | Denmark | 5 | 62 | Unresectable with PM | Close | 30–35 |
CIS-Dox (7.5 mg/m2- 1.5 mg/m2) |
6 | MOS since PM diagnosis = 14 months |
|
Khosrawipour, 2017 [68] |
Case series | Germany | 20 | Mean 64.9 | Unresectable with PM | Close | 30 |
CIS-Dox (7.5 mg/m2- 1.5 mg/m2) |
9.1 | Pathological regression rate = 35% |
N, Number of patients; MOS, Median overall survival from first PIPAC; PM, Peritoneal metastases; CIS, Cisplatin; Dox, Doxorubicin; Oxa, Oxaliplatin